HER2 pan-cancer species use the finger can wait for the next city of pyridine.

AuthorThe new drug, Her1, HER2 and HER4 tyrosine kinase irreversible oral inhibitors developed in China, has been approved in 2018 for the treatment of HER2-positive advanced breast cancerthis year ASCO's PHOEBEIII period data evidence that the phopentini-Kapethabin is superior to lapatini and Capethabin, and its position in breast cancer treatment has been greatly improvedHER2 mutation is also one of the most common driving mutation genes in lung cancer, with the insertion of an exon 20 most commonlyso far, the clinical treatment for her2 mutation of lung adenocarcinoma patients mainly to chemotherapy, but overall, with HER2 mutation of lung adenocarcinoma response to chemotherapy is not good, the overall survival rate of patients is difficult to be effectively improvedsome conventional anti-HER2 targeted drugs have not shown satisfactory efficacy in studies of HER2 mutation lung adenocarcinoma, and their toxic side effects can lead to intolerable rashes and diarrhea in patients, in practical clinical application, these drugs may not reach an effective treatment dose, resulting in poor treatment resultsand the National Drug Administration (NMPA) approved a targeted drug for the treatment of HER2-positive breast cancer, the researchers speculated that it might also have a better effect on NSCLC (lung adenocarcinoma) with her2 mutationsto test this hypothesis, the researchers first conducted a cytological experiment that found better anti-tumor effect on HER2 mutation NSCLC than afatinib and T-DM1, a multi-center phase II clinical study was conducted to treat the HER2 mutation NSCLC with pyridine, mainly in patients with HER2 mutation NSCLC who failed chemotherapygiven 400 mg oral to the above-mentioned patients for treatment above the second linehas the results of the patient's ORR of 31.7 percent and PFS for 6.8 months, oral pyridine has good safety, in NSCLC patients common adverse reactions are tolerable diarrhea, vomiting and other digestive symptomsthe results are reported at the ASCO annual meeting in 2019recently, the JCO journal also published a study of pyrith in the treatment of the late STAGE NSCLC for her2 mutationsresults are still brilliant, after breast cancer, and then take lung cancer, the strength of the practice of the use of good drug-wide cancer species conceptTrial Design Study is an open-label, one-arm phase II clinical study in which PATIENTs with HER2 exon 20 mutations (confirmed by the center laboratory) who have previously received at least one platinum-containing chemotherapy, to explore the efficacy and safety of pyridoxinib in this populationfrom October 20, 2016 to December 10, 2018, a total of 60 patients with HER2 mutation NSCLC were included, of which 96.7% (58) were in phase IV and 41.7% (25) had received two or more treatment optionsin-group patients receive treatment of pyritinib (400 mg, once daily) until disease progression, intolerable toxicity, or withdrawal of informed consentthe primary study endpoints are Objective Mitigation Rate (ORR), and secondary studies include Safety, Progression-Free Survival (PFS), Duration of Disease Progression (TTP), Duration of Mitigation (DoR), and Total Lifetime (OS)study data as of June 20, 2019, the results show that :1 the overall efficiency orR of 30%, all partially alleviated, 55.0% of patients with disease stability, disease control rate of 85%, 21.7% of patients showed disease stability for at least 24 weeks33.3% of patients with sustained responses in 18 people recorded reactions, with a median DOR of 6.9 months (95% CI, 4.9-11.1)(2) PFS and OS to data cut-off date, 65.0% of patients experienced no progression survival, with a median PFS of 6.9 months (95% CI, 5.5 to 8.3 months)12-month PFS rate was 22.5% (95% CI, 10.8% to 36.8%)50.0% of patients died on data deadlines, while median OS was 14.4 months (95% CI, 12.3 to 21.3 months)12 months oS rate was 69.1% (95% CI, 55.0% to 79.6%)(3) The efficiency of different HER2 mutation subtypes was 27.3% in 44 patients with 20 exosome stors inserted mutations, and the ORR was 16.7% in 6 patients with G776 mutation genes, 5 The ORR was 60.0% in patients with 20 exosome 9bp insertion mutations, 1 patient with V777L mutation had an ORR of 100%, and 4 patients with L755P mutation had an ORR of 25.0%The ORR was similar to 25.0% v 31.3% in patients with cerebral metastasis at the(4) pyrethinib, and 5.5 months v 6.9 months for median PFSHAD an ORR of 44.0% in patients who had previously received at least 2 line of chemotherapy, a 20.0% larger figure than those who had undergone 1 line of chemotherapy(5) safety in the median 10 treatment cycles, any level of treatment-related adverse reactions were reported in 98.3% of patients, most of which were level 1 or 2 adverse reactionsthe most common therapeutic adverse reactions in were diarrhea (91.7%), increased blood creatinine (30.0%), and vomiting (28.3%) 20% of diarrhea above level 3 as an innovative drug of China's original research, the date of its birth has been the attention of the chinese people, and its outstanding performance has been to the people of China to surprise: by virtue of the treatment of HER2-positive breast cancer, previously, the oxytocin has twice appeared in the "JCO" magazine, twice selected as an ASCO oral report in the field of HER2 mutant advanced lung cancer, has "completed" the domestic listed imported drugs, HER2 pan-cancer species use is within reach we also look forward to the future, in the near future, in the HER2 mutant advanced lung cancer in the stage III clinical study success, to win lung cancer indications, for patients to solve the urgent problem, not only for the benefit of Chinese patients, but also to the world's patients to share the well-being of China's "intellectual" Reference Source: 1 Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma Post-Based MOn- AndR original title: Research and development of the next city of pyrudinib - lung cancer, HER2 pan-cancer species use is within reach.